financetom
Business
financetom
/
Business
/
KKR Mulls To Buy Japan-Based Eye Care Company Topcon
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
KKR Mulls To Buy Japan-Based Eye Care Company Topcon
Mar 27, 2025 6:48 AM

KKR & Co Inc ( KKR )  is close to acquiring Tokyo-based eye care company Topcon Corp ( TOPCF ) (OTC:TOPCY).

According to Reuters, the private equity firm expects to sign the deal in the coming days. The price has not been disclosed yet.

The Japan-based manufacturer of optical equipment for ophthalmology and surveying has an enterprise value of around $2.53 billion as per data from Benzinga Pro.

Benzinga reached out to Topcon ( TOPCF ) for comments.

Also Read: Soleno Therapeutics Secures FDA Approval For Its First Commercial Drug For Rare Genetic Disorder

According to Reuters, a possible deal is in the works as Japan’s business reforms, growing investor activism, and a weak yen have made it easier for private equity firms to strike deals.

Topcon’s biggest shareholders are activist investors ValueAct Capital and Oasis Management Company, with stakes of 13.69% and 10.58%, respectively.

In its most recent quarterly earnings, Topcon ( TOPCF ) reported YTD December 2024 sales of 153.5 billion yen. That’s down 3.3% year over year, with an operating income of 0.8 billion yen.

The company said profits declined despite lower fixed costs due to reduced sales amid the ongoing demand slump.

For the eye care business, the company said despite steady sales, profits declined due to increased growth investment.

For fiscal year 2024, the company projects an operating profit of 7 billion yen and sales of 211 billion yen.

In December, Topcon ( TOPCF ) entered a bidding process with private equities to go private.

The Bloomberg reported that KKR and EQT were bidding for Topcon ( TOPCF ).

Read Next:

J&J Drug Combo Outperforms Leading Lung Cancer Treatment In Survival Study

Image: Shutterstock

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Amazon Prime Day Sales Likely to Reach $23.8 Billion, Adobe Analytics Says
Market Chatter: Amazon Prime Day Sales Likely to Reach $23.8 Billion, Adobe Analytics Says
Jul 7, 2025
09:01 AM EDT, 07/07/2025 (MT Newswires) -- Amazon.com's ( AMZN ) Prime Day sales this week are anticipated to rise 28.4% year over year to hit $23.8 billion across US retailers, according to Adobe Analytics, Reuters reported Monday. Amazon ( AMZN ) extended the event to 96 hours from July 8 to 11 this year, up from 48 hours in...
CoreWeave to Acquire Core Scientific in $9.0 Billion All-Stock Deal
CoreWeave to Acquire Core Scientific in $9.0 Billion All-Stock Deal
Jul 7, 2025
09:02 AM EDT, 07/07/2025 (MT Newswires) -- CoreWeave ( CRWV ) plans to acquire Core Scientific ( CORZ ) in an all-stock transaction valued at $9.0 billion, the companies said Monday. The transaction is expected to close in Q4 subject to approvals by regulators and Core Scientific ( CORZ ) shareholders. Upon closing, CoreWeave ( CRWV ) expects Core Scientific's...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Jasper Therapeutics to Halt Asthma Study After Drug Batch Issue; Shares Fall Pre-Bell
Jasper Therapeutics to Halt Asthma Study After Drug Batch Issue; Shares Fall Pre-Bell
Jul 7, 2025
09:02 AM EDT, 07/07/2025 (MT Newswires) -- Jasper Therapeutics ( JSPR ) said Monday it is shutting down its asthma trial after discovering a faulty batch of its experimental drug was used to treat individuals who were enrolled in a trial evaluating briquilimab. The company also said it is halting development in severe combined immunodeficiency and may restructure operations to...
Copyright 2023-2026 - www.financetom.com All Rights Reserved